Ultragenyx Pharmaceutical shares are trading lower after the company announced results from the Phase 3 Aspire study for apazunersen did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index.